Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition

Boehringer IngelheimAs part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world, Boehringer Ingelheim and Ashoka's Changemakers® announced the launch of the "Making More Health" Competition.

This worldwide competition invites the most innovative models and solutions that are transforming the field of health today.The competition will recognize and award US $10,000 to each of three winners whose solutions are working to achieve individual, family, and community well-being.

The Making More Health competition seeks solutions that work along the entire continuum of health, from prevention and lifestyle, to detection and treatment. Eligible entries include those that increase access to quality health services and treatment; promote prevention, early detection, and diagnosis; empower individuals, families, and communities to address their health issues; or target vulnerable and underserved populations. Entries will be accepted until September 21, 2011.

"The Making More Health competition reflects Boehringer Ingelheim's commitment to supporting leadership and innovation in healthcare and to improving health for individuals, families, and communities," said Jean Scheftsik de Szolnok, Vice-President Southern Europe for Boehringer Ingelheim. "By sourcing new approaches to healthcare delivery, the competition will contribute to ensuring a sustainable future in which good health for everyone is possible."

Participants can submit competition entries through the www.changemakers.com/morehealth website where they can discuss and share ideas about different approaches to health, comment on entries, and vote for winners. An expert panel of judges, including Dr. Andreas Barner, chairman of the board of managing directors for Boehringer Ingelheim and Aman Bhandari, senior advisor to the CTO at the US Department of Health and Human Services, will select a pool of finalists, and the Changemakers online community will vote to determine the three winning entries.

"We are excited about the opportunity our partnership with Boehringer Ingelheim has offered to tap the drive and creativity of changemakers from around the globe and make their solutions visible to all who are interested in finding them," said Diana Wells, president of Ashoka. "Boehringer Ingelheim is taking an important leadership role in the sector by recognizing the value that surfacing community solutions for health is critical to their core business."

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Social responsibility is a core element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of its global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic values of all of Boehringer Ingelheim's endeavors.

About Ashoka's Changemakers
Ashoka's Changemakers is an online community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and scaling ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and vision for an "Everyone a Changemaker" world by creating a place where the best ideas in social innovation can be shared, refined, and funded.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]